Funds are buying hospitals in the 50 to 250 bed range. The price they pay turns on evidence most owners have never been asked to produce.
Every challenge is tagged to a lens, and every challenge is answered by a named service on this page.
Single specialty hospitals require ₹28–35 Cr per 100 beds against ₹25–28 Cr for multi-specialty facilities - a 10–12% premium - due to specialised infrastructure. At a 200-bed greenfield setup this can add ₹20–30 Cr in avoidable overrun before a single patient is served.
Source: ICRA 2024 How we solve thisGovernment package caps on inpatient care erode gross IPD margins to 10–15% against 25–35% for OPD. ICU stays are capped at ₹1,800 per day under PM-JAY against private rates of ₹4,000–₹6,000, and a hospital cannot offset IPD losses with OPD profits.
Source: PM-JAY; UIIC/NHM; KPMG 2024 How we solve thisLand acquisition represents 30–40% of project costs in tier 2/3 locations against 15–20% in metros. Combined with 12–18 month development timelines and low hospital density, return on investment is typically delayed to 8–10 years.
Source: NHB 2023/2024; ICRA 2024 How we solve thisAverage bed turnover runs at 1.5× per day against 2.0× at multi-specialty hubs, creating 25–30% underutilisation in low-case-mix specialties. Capacity utilisation sits at 50–60% in tier 2/3 against 70–75% in metros, and the benchmark a buyer expects is 75% and above at a matured facility.
Source: HIMS 2023; KPMG India, December 2025 How we solve thisA hospital needs 10–15 dedicated staff per 100 beds for NHM compliance, state health department audits and medical council reporting, against 5–7 per 100 OPD seats at a clinic. Policy volatility adds constant protocol revision, costing 2–3% of the admin budget.
Source: NHB 2023; NHM 2024 How we solve thisStandalone hospitals convert referrals at 25–30% against 40–50% for clinics inside integrated networks, reducing OPD revenue by 15–20%. Accreditation status also changes the rate you are paid: PMJAY empanelment with NABH entry-level earns a 10% higher package rate, full accreditation 15%.
Source: Apollo referral study; Press Information Bureau on PMJAY package rates How we solve thisLand title, clinical establishment registration, pharmacy and imaging licences and doctor contracts are what a fund opens first. Tax exposures and title questions stall more Indian hospital deals than clinical issues do, and an MIS whose numbers cannot be reconciled turns into a discount.
Source: KPMG India, December 2025 How we solve thisThe work is organised across six lenses: innovation, efficiency, marketing and sales, financial structuring, regulation and compliance, and delivery.
Selecting and deploying hospital information systems, PACS, telemedicine platforms, clinical dashboards for medical directors, and AI-assisted diagnostics. We manage vendor selection, contract negotiation and implementation oversight.
HIS · PACS · AI DiagnosticsPilots designed with a pre-agreed endpoint, a pre-agreed reader and a pre-agreed decision date - so the outcome is a purchase decision rather than an indefinite evaluation.
Evidence GenerationKey opinion leaders who actually use the product, generating real-world evidence in Indian clinical settings rather than extrapolating from trials run elsewhere on different populations.
RWE · Clinical AdvocacyThe person questioning the theatre list has run one, and the person reading the case mix has treated it. Three to five days inside the asset, examining throughput, occupancy, payer mix, earnings quality and the records a fund opens first.
Buy-SideClinicians design the programme around a defined catchment population, a clinical endpoint and a measurement plan, turning a funding request into something a CSR committee can approve.
Programme DesignTelemedicine deployment and AI-assisted screening camps for CSR-funded public health programmes reaching tier 2, tier 3 and rural catchments - the same clinical and technical rigour we apply to a funded venture, applied to a funded programme.
Telemedicine · AI ScreeningEnd-to-end RCM audit and overhaul - billing accuracy, claim submission timelines, denial management and insurance reconciliation. Hospitals typically recover 8–15% of top-line revenue through systematic RCM reform.
Counters: Inpatient Margin CompressionInventory rationalisation, vendor consolidation, consumable standardisation and pharmacy cost management. We benchmark supply costs against national peers and implement group purchasing structures.
Procurement · Inventory · VendorsTheatre utilisation analysis, bed occupancy modelling, length of stay read against case mix, and diagnostic equipment yield assessment. We unlock idle capacity to increase revenue per square foot without capital expenditure.
Counters: Bed Turnover & Utilisation DragTime-motion studies, departmental process mapping and cross-functional workflow redesign, plus SOP rollout and a management information system that stands up to outside scrutiny rather than one rebuilt in a panic before diligence.
Counters: Administrative & Compliance LoadThe person questioning the theatre list has run one, and the person reading the case mix has treated it. Three to five days inside the asset, examining throughput, occupancy, payer mix, earnings quality and the records a fund opens first.
Buy-SideSynergy modelling built on real clinical workflow rather than an org chart - what actually merges, what cannot, and which of the projected savings survive contact with a theatre schedule.
Buy-SideEmpanelment under Ayushman Bharat, PMJAY, CGHS, ECHS and state insurance schemes, plus TPA and insurer negotiation - converting quality credentials into a payer-access advantage and a revenue stream.
Counters: Referral Conversion GapFor hospitals seeking CSR funding, government partnerships or impact investor capital - public health programme frameworks, HEOR studies and social impact measurement aligned with NHM, PMJAY and WHO standards.
HEOR · CSR · Public HealthGetting devices, diagnostics and software physically deployed inside the hospitals we hold relationships with - with the clinical champion, the procurement route and the budget line identified before the conversation starts.
Real deployment inside partner hospitalsEntry aligned to the institution's actual buying cycle and formulary review calendar. Missing the cycle by a month costs a quarter; we time the approach to the committee, not to your runway.
Buying Cycles · FormularyPublic tender preparation, qualification criteria review, and empanelment under central and state health schemes - the route to volume that most private-sector GTM plans overlook entirely.
Tenders · Public ProcurementChannel design, distributor selection and margin structure for physical products across a market where the last mile determines whether a good device ever reaches a patient.
Channel · DistributionExpansion into Gulf and South East Asian markets through partner institutions, with regulatory pathway, pricing and local partner selection handled as one workstream rather than three.
International ExpansionMedical tourism and referral pathway design, plus post-launch adoption tracking that tells you whether the product is being used after it was bought - the metric that determines renewal.
Referral · Post-Launch AdoptionApproaching hospital chains, pharma groups and global health funds seeking Indian acquisitions - and presenting your asset to them ourselves, on your mandate, rather than forwarding it to whoever is buying.
Counters: Exit ConstrictionQualified projects taken directly to corporate CSR teams, foundations and family offices with healthcare in their giving mandate, rather than asking donors to go looking.
Donor MatchingWe benchmark your price against scheme caps, private rates and incumbent offers, then identify a reimbursement pathway that works for both the buying institution and your unit economics.
Pricing · ReimbursementBuilding the universe of realistic targets or realistic acquirers, screened on clinical fit and integration feasibility rather than on a screen of financials alone.
Buy-SideHealthcare comparables that account for city tier, payer mix and asset type - because standalone specialty assets and listed multi-specialty networks are not the same trade, and pricing them alike is how deals go wrong.
Buy-Side · Sell-SideThe data room built to what a fund will actually open first, with a diligence readiness scorecard measured against the same list. Preparation done in the eighteen months before signing is what shapes the terms you can accept.
Counters: Records, MIS & Diligence ReadinessPutting the clinical asset into language investors read correctly, and supporting the quality-of-earnings work - because earnings that do not survive verification are the single most common reason an offer is cut after diligence begins.
Sell-SidePreparing hospitals for NABH, JCI, NABL and NQA certification cycles. A PMJAY empanelled hospital with NABH entry-level certification earns a 10% higher package rate, and full accreditation 15%.
NABH · JCI · NABLAccreditation status, clinical governance, licensing, and the regulatory exposures that surface after close if nobody clinically qualified looked before it.
Buy-SideSite selection, master planning, regulatory clearances and project management for new hospital builds or acquisition-led expansion into tier 2 and tier 3 markets - with design-to-cost discipline that strips out the per-bed capex premium.
Counters: Per-Bed Capex Premium & Real Estate Friction in Tier 2/3The work after close, where most value is actually lost. Protocol harmonisation, consultant retention, procurement consolidation and the MIS unification that lets the combined entity report as one.
Buy-Side · Post-CloseSpecification, procurement, installation, staff training and commissioning for funded capital equipment, so the asset ends up in clinical use rather than in a store room.
Capex · CommissioningMost owners begin with a diagnostic visit and operational work. Some later pursue a raise or sale. Keeping these engagements separate lets you commission operational help without committing to a transaction.
Throughput, revenue cycle, procurement, accreditation, records and diligence readiness.
Data room, valuation defence, buyer outreach and representation through to close.
Scope and fees are settled after the first conversation, against the size of your hospital and the depth of work you want done. The diagnostic visit can be commissioned on its own without any commitment to what follows.
Fifty to two hundred fifty bed hospitals in tier 2 and tier 3 markets. Let us talk through your P&L and your next raise.